公开(公告)号：US20130196356A1

公开(公告)日：2013-08-01

申请号：US13824307

申请日：2011-09-13

Applicant: Graham Stuart Jackson ,  John Collinge ,  Julie Ann Edgeworth

Inventor： Graham Stuart Jackson ,  John Collinge ,  Julie Ann Edgeworth

IPC: G01N33/68

CPC classification number: G01N33/6896 ,  G01N33/6893 ,  G01N2333/70596 ,  G01N2800/2828

Abstract: The invention relates to a method for detection of abnormal PrP in a sample of blood or urine, said method comprising: (a) diluting the sample with buffer to comprise final concentrations of (i) 10 mM to 500 mM buffer agent; (ii) 1% to 10% w/v bovine serum albumin; and (iii) 1% to 8% w/v CHAPS; (b) adding steel particles and incubating to allow PrP binding; (c) washing the steel particles to remove diluted sample; and (d) detecting abnormal PrP captured on the steel particles using antibody capable of binding said abnormal PrP. The invention also provides compositions and kits.

Abstract translation: 本发明涉及一种用于检测血液或尿样品中异常PrP的方法，所述方法包括：（a）用缓冲液稀释样品以包含（i）10mM至500mM缓冲剂的终浓度; （ii）1％至10％w / v牛血清白蛋白; 和（iii）1％至8％w / v CHAPS; （b）加入钢颗粒并孵育以允许PrP结合; （c）洗涤钢颗粒以除去稀释的样品; 和（d）使用能够结合所述异常PrP的抗体检测在钢颗粒上捕获的异常PrP。 本发明还提供组合物和试剂盒。

公开(公告)号：US09028801B2

公开(公告)日：2015-05-12

申请号：US11792686

申请日：2005-12-07

Applicant: Malcolm Andrew Ward ,  John Collinge ,  Graham Stuart Jackson ,  Emma McGregor ,  Nicola Louise Leeds ,  James Campbell ,  Jules Arthur Westbrook ,  Helen Louise Byers

Inventor： Malcolm Andrew Ward ,  John Collinge ,  Graham Stuart Jackson ,  Emma McGregor ,  Nicola Louise Leeds ,  James Campbell ,  Jules Arthur Westbrook ,  Helen Louise Byers

IPC: A61B5/145 ,  G01N33/48 ,  C07K14/805 ,  C07K14/75 ,  C07K14/705 ,  G01N33/68

CPC classification number: G01N33/6896 ,  G01N2800/2828 ,  G01N2800/56 ,  G01N2800/60

Abstract: The invention relates to a method of diagnosis of vCJD in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an increased concentration of a protein in the diagnostic sample, compared with a sample of a control human subject, the protein being: beta-actin (SwissProt Acc. No. P60709), apolipoprotein A-IV precursor (SwissProt Acc. No. P06727); haptoglobin beta-chain consisting of residues 162-406 (SwissProt Acc. No. P00738); haemoglobin beta chain (SwissProt Acc. No. P02023); or alpha-1-antitrypsin (SwissProt Acc. No. P01009); or a decreased concentration of a protein in the diagnostic sample, compared with a sample of a control, normal human subject, the protein being plasma protease (C1) inhibitor precursor (SwissProt Acc. No. P05155); complement component 1, s sub-component (SwissProt Acc. No. P09871); butyrylcholinesterase precursor (SwissProt Acc. No. P06276); complement component C4B (SwissProt Acc. No. P01028); lumican (SwissProt Acc. No. P51884); alpha-fibrinogen precursor (SwissProt Acc. No. P02671); IGHG4 protein (Swiss Prot Acc. No. Q8TC63) or immunoglobulin lambda heavy chain. Other marker proteins are also disclosed.

Abstract translation: 本发明涉及一种诊断样品中vCJD的方法，该方法是从人体受试者获取的有效身体组织的诊断样本中，其与检测样本中的蛋白质的浓度相比较，与对照人受试者相比， 蛋白质是：β-肌动蛋白（SwissProt Acc.P60709），载脂蛋白A-IV前体（SwissProt Acc.Po6727）; 由残基162-406组成的触珠蛋白β链（SwissProt Acc.P00738）; 血红蛋白β链（SwissProt Acc。编号P02023）; 或α-1-抗胰蛋白酶（SwissProt Acc。编号P01009）; 或与对照组，正常人受试者的样品，蛋白质是血浆蛋白酶（C1）抑制剂前体（SwissProt Acc.No.P05155））相比，诊断样品中蛋白质的浓度降低。 补充成分1的子成分（SwissProt Acc。No.P09871）; 丁酰胆碱酯酶前体（SwissProt Acc.Po6276）; 补体成分C4B（SwissProt Acc。No.P01028）; lumican（SwissProt Acc。No. P51884）; α-纤维蛋白原前体（SwissProt Acc。编号P02671）; IGHG4蛋白（Swiss Prot Acc。No.Q8TC63）或免疫球蛋白λ重链。 还公开了其它标记蛋白。

公开(公告)号：US20080213802A1

公开(公告)日：2008-09-04

申请号：US11792686

申请日：2005-12-07

Applicant: Malcolm Andrew Ward ,  John Collinge ,  Graham Stuart Jackson ,  Emma McGregor ,  Nicola Louise Leeds ,  James Campbell ,  Jules Arthur Westbrook ,  Helen Louise Byers

Inventor： Malcolm Andrew Ward ,  John Collinge ,  Graham Stuart Jackson ,  Emma McGregor ,  Nicola Louise Leeds ,  James Campbell ,  Jules Arthur Westbrook ,  Helen Louise Byers

IPC: G01N33/53 ,  C12Q1/02 ,  C12Q1/46

CPC classification number: G01N33/6896 ,  G01N2800/2828 ,  G01N2800/56 ,  G01N2800/60

Abstract: The invention relates to a method of diagnosis of vCJD in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an increased concentration of a protein in the diagnostic sample, compared with a sample of a control human subject, the protein being: beta-actin (SwissProt Ace. No. P60709), apolipoprotein A-IV precursor (SwissProt Acc. No. P06727); haptoglobin beta-chain consisting of residues 162-406 (SwissProt Acc. No. P00738); haemoglobin beta chain (SwissProt Ace. No. P02023); or alpha-1-antitrypsin (SwissProt Ace. No. P01009); or a decreased concentration of a protein in the diagnostic sample, compared with a sample of a control, normal human subject, the protein being plasma protease (C1) inhibitor precursor (SwissProt Acc. No. P05155); complement component 1, s sub-component (SwissProt Acc. No. P09871); butyrylcholinesterase precursor (SwissProt Acc. No. P06276); complement component C4B (SwissProt Acc. No. P01028); lumican (SwissProt Ace. No. P51884); alpha-fibrinogen precursor (SwissProt Ace. No. P02671); IGHG4 protein (Swiss Prot Ace. No. Q8TC63) or immunoglobulin lambda heavy chain. Other marker proteins are also disclosed.

Abstract translation: 本发明涉及一种诊断样品中vCJD的方法，该方法是从人体受试者获取的有效身体组织的诊断样本中，其与检测样本中的蛋白质的浓度相比较，与对照人受试者相比， 蛋白质是：β-肌动蛋白（SwissProt Ace.No.P60709），载脂蛋白A-IV前体（SwissProt Acc.Po6727）; 由残基162-406组成的触珠蛋白β链（SwissProt Acc.P00738）; 血红蛋白β链（SwissProt Ace。编号P02023）; 或α-1-抗胰蛋白酶（SwissProt Ace.Po1009）; 或与对照组，正常人受试者的样品，蛋白质是血浆蛋白酶（C1）抑制剂前体（SwissProt Acc.No.P05155））相比，诊断样品中蛋白质的浓度降低。 补充成分1的子成分（SwissProt Acc。No.P09871）; 丁酰胆碱酯酶前体（SwissProt Acc.Po6276）; 补体成分C4B（SwissProt Acc。No.P01028）; lumican（SwissProt Ace。No. P51884）; α-纤维蛋白原前体（SwissProt Ace。编号P02671）; IGHG4蛋白（Swiss Prot Ace。No.Q8TC63）或免疫球蛋白λ重链。 还公开了其它标记蛋白。

公开(公告)号：US10288627B2

公开(公告)日：2019-05-14

申请号：US13824307

申请日：2011-09-13

Applicant: Graham Stuart Jackson ,  John Collinge ,  Julie Ann Edgeworth

Inventor： Graham Stuart Jackson ,  John Collinge ,  Julie Ann Edgeworth

IPC: G01N33/68

Abstract: The invention relates to a method for detection of abnormal PrP in a sample of blood or urine, said method comprising: (a) diluting the sample with buffer to comprise final concentrations of (i) 10 mM to 500 mM buffer agent; (ii) 1% to 10% w/v bovine serum albumin; and (iii) 1% to 8% w/v CHAPS; (b) adding steel particles and incubating to allow PrP binding; (c) washing the steel particles to remove diluted sample; and (d) detecting abnormal PrP captured on the steel particles using antibody capable of binding said abnormal PrP. The invention also provides compositions and kits.